Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease.

Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See why NVS stock earns a buy rating.

A Novartis executive said “it’s too early to say” whether the company would submit an experimental myelofibrosis drug for approval this year, amid questions about the medicine’s data profile.

Novartis is moving through a long-winded transition phase right now. This process is set to culminate in the upcoming spin-off of the generic drug unit, Sandoz, later this year. Following this ...

Upon option exercise, Novartis will acquire full global rights to the BDM platform. Sironax is eligible to receive up to $175 million in upfront and near-term payments. About Sironax ...

WALTHAM, Mass., July 9, 2025 /PRNewswire/ -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today ...